Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial

Cantini, 2020, Emerging treatments for malignant pleural mesothelioma: where are we heading?, Front Oncol, 10, 343, 10.3389/fonc.2020.00343 Jassem, 2008, Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma, J Clin Oncol, 26, 1698, 10.1200/JCO.2006.09.9887 Fennell, 2021, Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial, Lancet Oncol, 22, 1530, 10.1016/S1470-2045(21)00471-X Novello, 2019, MS13·06 role of second line chemotherapy and new target treatment in recurrent mesothelioma, J Thorac Oncol, 14, S182, 10.1016/j.jtho.2019.08.362 Kindler, 2018, Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline, J Clin Oncol, 36, 1343, 10.1200/JCO.2017.76.6394 Stebbing, 2009, The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma, Lung Cancer, 63, 94, 10.1016/j.lungcan.2008.04.001 Fennell, 2021, A randomized phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma, J Clin Oncol, 39 Ceresoli, 2016, Immune checkpoint inhibitors in malignant pleural mesothelioma: promises and challenges, Expert Rev Anticancer Ther, 16, 673, 10.1080/14737140.2016.1191951 Hassan, 2008, Mesothelin targeted cancer immunotherapy, Eur J Cancer, 44, 46, 10.1016/j.ejca.2007.08.028 Golfier, 2014, Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect, Mol Cancer Ther, 13, 1537, 10.1158/1535-7163.MCT-13-0926 Chalouni, 2018, Fate of antibody-drug conjugates in cancer cells, J Exp Clin Cancer Res, 37, 20, 10.1186/s13046-017-0667-1 Hassan, 2020, First-in-human, multicenter, phase I dose escalation and expansion study of anti-mesothelin antibody-drug conjugate anetumab ravtansine in advanced or metastatic solid tumors, J Clin Oncol, 38, 1824, 10.1200/JCO.19.02085 Singh, 2020, Abstract 1808: loss of BAP1/BRCA1 counteracts spindle assembly checkpoint activation by the anti-mesothelin antibody drug-conjugate anetumab ravtansine, Cancer Res, 80, 10.1158/1538-7445.AM2020-1808 Hmeljak, 2018, Integrative molecular characterization of malignant pleural mesothelioma, Cancer Discov, 8, 1548, 10.1158/2159-8290.CD-18-0804 Kumar, 2019, Retrospective response analysis of BAP1 expression to predict the clinical activity of systemic cytotoxic chemotherapy in mesothelioma, Lung Cancer, 127, 164, 10.1016/j.lungcan.2018.12.004 Zalcman, 2016, Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial, Lancet, 387, 1405, 10.1016/S0140-6736(15)01238-6 Byrne, 2004, Modified RECIST criteria for assessment of response in malignant pleural mesothelioma, Ann Oncol, 15, 257, 10.1093/annonc/mdh059 Zucali, 2008, Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma, Cancer, 112, 1555, 10.1002/cncr.23337 Mendoza, 2019, Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM), J Patient Rep Outcomes, 3, 34, 10.1186/s41687-019-0122-5 Cristaudo, 2007, Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer, Clin Cancer Res, 13, 5076, 10.1158/1078-0432.CCR-07-0629 Bueno, 2016, Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations, Nat Genet, 48, 407, 10.1038/ng.3520 Phallen, 2017, Direct detection of early-stage cancers using circulating tumor DNA, Sci Transl Med, 9, 10.1126/scitranslmed.aan2415 Hylebos, 2018, Tumor-specific genetic variants can be detected in circulating cell-free DNA of malignant pleural mesothelioma patients, Lung Cancer, 124, 19, 10.1016/j.lungcan.2018.07.028 Wang, 2004, A requirement for breast-cancer-associated gene 1 (BRCA1) in the spindle checkpoint, Proc Natl Acad Sci USA, 101, 17108, 10.1073/pnas.0407585101 Busacca, 2021, BRCA1/MAD2L1 deficiency disrupts the spindle assembly checkpoint to confer vinorelbine resistance in mesothelioma, Mol Cancer Ther, 20, 379, 10.1158/1535-7163.MCT-20-0363 Zhang, 2021, Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment, Nat Commun, 12